Dr. Alfred Server was a partner in the Technology Transactions and Licensing Practice Group. He joined the firm in 1993 and retired in 2012. Dr. Server focused his practice on corporate partnering in the life sciences field.
Dr. Server has represented the firm's clients in some of the most significant and highly regarded strategic alliance transactions in the life sciences industry, including Incyte Corporation’s recent licensing deals with Novartis and Eli Lilly and Company relating to the development and commercialization of drug candidates for the treatment of cancer and inflammation, totaling up to $2 billion in potential payments; TransTech Pharma's recent agreement with Forest Laboratories relating to a novel class of glucose-lowering agents for the treatment of diabetes and valued at up to $1.105 billion and its agreement with Pfizer, Inc. relating to the development and commercialization of drug candidates for the treatment of Alzheimer's disease; Millennium Pharmaceuticals' $500 million marketing deal for Velcade (bortezomib), a proteasome inhibitor for multiple myeloma with Ortho Biotech Products, LP, a Johnson & Johnson company; and Idenix Pharmaceuticals' agreement with Novartis Pharma AG, focused on viral drugs for hepatitis and valued at up to $862 million.
Dr. Server was involved in the establishment of The SNP Consortium, a novel, nonprofit consortium made up of 10 of the world's leading pharmaceutical companies and a British charity. The consortium was established to identify and develop a map of genetic variation in the human genome, which has been made publicly available.
Dr. Server also advised British nonprofit organization GALVmed (the Global Alliance for Livestock Veterinary Medicines) in setting up a manufacturing and distribution chain for a vaccine that can save the lives of cattle relied upon for food and economic security by farmers and herders in Tanzania. He was recognized at an event in the city of Arusha celebrating the successful registration of the vaccine with the Tanzanian government.
Companies for whom Dr. Server has worked include: Millennium Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Wyeth; Becton, Dickinson & Company; Novartis Pharmaceuticals; Incyte Corporation; MethylGene, Inc.; Idenix Pharmaceuticals, Inc.; TransTech Pharma, Inc.; Infinity Pharmaceuticals, Inc. and Transkaryotic Therapies Inc. (TKT).
Dr. Server received a JD degree from Harvard Law School. He received an AB degree, summa cum laude, from Princeton University, where he was elected to Phi Beta Kappa. His biomedical training includes an MD degree and a PhD degree (neurological sciences) from Stanford University, a medical internship at Peter Bent Brigham Hospital (a Harvard teaching hospital and predecessor of Brigham and Women’s Hospital), a neurology residency at Johns Hopkins Hospital, and post-doctoral fellowships in neurovirology and molecular biology at Johns Hopkins University and Harvard University. Prior to joining the firm, Dr. Server was a founder and the research director of a biotechnology company.
Honors & Awards
- Consistently ranked in the PLC Cross-border Life Sciences Handbook as a leading lawyer in the life sciences commercial and corporate partnering category for the US. Dr. Server is one of only two lawyers in the US to receive the handbook's highest ranking in the life sciences corporate partnering practice area since 2001.
- Recognized as a national leader in the life sciences: commercial field in Chambers USA: America's Leading Lawyers in Business 2012
- Recognized as one of the leading patent licensing transactional lawyers in the US in the 2011, 2012 and 2013 editions of The Legal 500 United States
- Recognized as a life sciences star for outstanding transactional work in the 2012 inaugural edition of LMG Life Sciences
Insights & News
JD, Harvard Law School, 1994
MD, Stanford University, 1977
PhD, Neurological Sciences, Stanford University, 1976
AB, Princeton University, 1970summa cum laude Phi Beta Kappa